当前位置: 首页 > 详情页

Differential Activation of mTOR Complex 1 Signaling in Human Brain with Mild to Severe Alzheimer's Disease

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

机构: [a]Department of Neurology, Xuan Wu Hospital of Capital Medical University, Beijing, China [b]Department of Neurosurgery, Xuan Wu Hospital of Capital Medical University, Beijing, China [c]Buck Institute for Research on Aging, Novato, CA, USA [d]Department of Physiology and the Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio, TX, USA [e]Department of Pharmacology and Neuroscience, Institute for Aging and Alzheimer’s Disease Research, University of North Texas Health Science Center at Fort Worth, Fort Worth, TX, USA
出处:
ISSN:

关键词: Alzheimer's disease cognitive impairment mTOR RagC rapamycin

摘要:
Mammalian target of rapamycin (mTOR) signaling has been suggested to be effective in modifying cognitive status in animal models of Alzheimer's disease (AD), but little is known about its role in AD patients. We hereby tested whether mTOR signaling was activated and whether activated mTOR signaling was related to the degree of cognitive deficits in patients with AD. Autopsy brain hippocampal tissues were obtained from controls and patients with AD and Western blots were performed using antibodies against mTOR signaling molecules and RagC, an upstream component of mTOR complex 1 (mTORC1) signaling. We found that expression of mTOR/p-mTOR and its downstream targets S6/p-S6 and Raptor/p-Raptor were expressed in the control and AD hippocampus. The expression levels of these signaling molecules were significantly increased in the hippocampus at the severe stages of AD, compared to controls and other stages of AD. Interestingly, Rictor expression level was unaltered. In addition, RagC was increased in the hippocampus at the early, moderate, and severe stages of AD. Our data indicate that mTORC1, but not mTORC2, was activated in the AD brains and that the level of mTOR signaling activation was correlated with cognitive severity of AD patients.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2013]版:
大类 | 2 区 医学
小类 | 3 区 神经科学
最新[2025]版:
大类 | 3 区 医学
小类 | 3 区 神经科学
JCR分区:
出版当年[2012]版:
Q2 NEUROSCIENCES
最新[2023]版:
Q2 NEUROSCIENCES

影响因子: 最新[2023版] 最新五年平均 出版当年[2012版] 出版当年五年平均 出版前一年[2011版] 出版后一年[2013版]

第一作者:
第一作者机构: [a]Department of Neurology, Xuan Wu Hospital of Capital Medical University, Beijing, China
通讯作者:
通讯机构: [*1]Department of Pharmacology and Neuroscience, Institute for Aging and Alzheimer’s Disease Research, University of North Texas Health Science Center at Fort Worth, FortWorth, TX 76107, USA.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:17006 今日访问量:0 总访问量:906 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院